FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to new bispecific antibodies, and can be used in medical practice. The invention discloses a bispecific antibody that specifically binds to the CD3 surface antigen of immune cells and the BCMA antigen on the surface of tumor cells. Such an antibody is capable of binding with high affinity to human CD3 cells and inducing the proliferation of immune T cells, thereby promoting the destruction of cancer cells in the subject's body.
EFFECT: invention may be applicable in the manufacture of a medicament for the treatment or relief of symptoms of plasma cell disorders and other B cell disorders, as well as for the treatment of autoimmune diseases associated with BCMA expression, including multiple myeloma.
25 cl, 11 dwg, 6 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
| CD3 BINDING ANTIBODIES | 2017 |
|
RU2807216C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2790288C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
| CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
| MODIFIED J-STRAIN | 2015 |
|
RU2761118C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
